$270 Million is the total value of Sio Capital Management, LLC's 47 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MSAC | MEDICUS SCIENCES ACQUISITION | $23,392,610 | +1.7% | 2,323,000 | 0.0% | 8.65% | +18.4% | |
| BCYC | BICYCLE THERAPEUTICS PLCsponsored ads | $20,229,380 | +27.3% | 683,425 | 0.0% | 7.48% | +48.1% | |
| CI | CIGNA CORP | $17,432,129 | +19.4% | 52,611 | 0.0% | 6.45% | +39.0% | |
| CBAY | CYMABAY THERAPEUTICS INC | $3,483,675 | +79.1% | 555,610 | 0.0% | 1.29% | +108.4% | |
| HSAQ | HEALTH SCIENCES ACQUISITIONS CORP 2 | $2,495,000 | +0.8% | 250,000 | 0.0% | 0.92% | +17.4% | |
| EUCRU | EUCRATES BIOMEDICAL ACQUISITION CORP.unit 10/23/2027 | $2,481,767 | -0.4% | 248,674 | 0.0% | 0.92% | +15.9% | |
| ISEE | IVERIC BIO INCput | $1,849,824 | +19.3% | 86,400 | 0.0% | 0.68% | +38.7% | |
| MRUS | MERUS NV | $1,360,633 | -22.8% | 87,953 | 0.0% | 0.50% | -10.2% | |
| IDYA | IDEAYA BIOSCIENCES INC | $1,271,900 | +21.8% | 70,000 | 0.0% | 0.47% | +41.6% | |
| TYRA BIOSCIENCES INC | $1,156,408 | -13.5% | 152,159 | 0.0% | 0.43% | +0.7% | ||
| MBRX | MOLECULIN BIOTECH INC | $1,099,064 | +0.0% | 1,036,853 | 0.0% | 0.41% | +16.3% | |
| FUSN | FUSION PHARMACEUTICALS INC | $820,411 | +4.6% | 260,448 | 0.0% | 0.30% | +21.7% | |
| CNTB | CONNECT BIOPHARMA HOLDINGS LTDads | $518,665 | -32.7% | 597,678 | 0.0% | 0.19% | -21.6% | |
| ASLN | ASLAN PHARMACEUTICALS LTDads | $457,473 | -39.9% | 1,270,758 | 0.0% | 0.17% | -30.2% | |
| ELEV | ELEVATION ONCOLOGY INC | $341,744 | -15.8% | 359,731 | 0.0% | 0.13% | -2.3% | |
| NXTC | NEXTCURE INC | $183,300 | -48.8% | 130,000 | 0.0% | 0.07% | -40.4% | |
| VINC | VINCERX PHARMA INC | $104,090 | -26.2% | 102,049 | 0.0% | 0.04% | -15.6% | |
| NYXOAH SA | $80,389 | -20.4% | 16,110 | 0.0% | 0.03% | -6.2% | ||
| NLTX | NEOLEUKIN THERAPEUTICS INC | $19,501 | -22.0% | 38,312 | 0.0% | 0.01% | -12.5% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VIKING THERAPEUTICS INC | 24 | Q3 2023 | 3.4% |
| UNITED THERAPEUTICS ORD | 23 | Q3 2023 | 8.3% |
| CARDINAL HEALTH ORD | 20 | Q2 2022 | 7.2% |
| SANOFI SA | 19 | Q3 2022 | 9.8% |
| MEDTRONIC PLC | 18 | Q3 2023 | 5.2% |
| CATALYST BIOSCIENCES INC | 18 | Q3 2021 | 17.8% |
| PFENEX ORD | 18 | Q4 2019 | 5.9% |
| AEGLEA BIOTHERAPEUTICS INC | 18 | Q1 2023 | 1.1% |
| HCA HEALTHCARE INC | 17 | Q2 2022 | 5.5% |
| MCKESSON ORD | 17 | Q1 2022 | 6.0% |
View Sio Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Modular Medical, Inc. | February 13, 2023 | 1,091,479 | 10.0% |
| Cellectar Biosciences, Inc. | February 10, 2022 | ? | ? |
| CURIS INC | February 10, 2022 | 3,866,645 | 4.2% |
| Salarius Pharmaceuticals, Inc. | February 10, 2022 | 1,354,291 | 3.0% |
| Larimar Therapeutics, Inc. | February 16, 2021 | 188,661 | 1.2% |
| ACHIEVE LIFE SCIENCES, INC. | February 14, 2020 | ? | ? |
| Bionano Genomics, Inc | February 14, 2020 | 1,210,821 | 4.6% |
| Brickell Biotech, Inc. | February 14, 2020 | ? | ? |
| Trillium Therapeutics Inc. | February 14, 2020 | 2,751,186 | 9.8% |
| ZAFGEN, INC. | February 14, 2020 | 2,283,164 | 6.1% |
View Sio Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| SC 13G | 2023-02-13 |
| 13F-HR | 2022-11-14 |
View Sio Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.